文献速递银屑病与炎症性皮肤病皮肤感染

女性银屑病患者对生物制剂治疗满意度更低且副作用更多:BioCAPTURE 注册研究

Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-07-07

本研究基于前瞻性多中心日常实践 BioCAPTURE 注册数据,纳入 315 例银屑病患者共 396 个治疗疗程,使用 TSQM 问卷纵向分析生物制剂治疗满意度性别差异。线性混合模型显示女性在副作用维度(P=0.05)和整体满意度维度(P=0.01)评分显著低于男性,且女性报告更多相关不良事件(率比 1.79;P<0.001),包括真菌感染(率比 2.20;P=0.001)和单纯疱疹感染(率比 3.25;P=0.005)。

要点

  • 女性银屑病患者生物制剂治疗中副作用满意度及整体满意度均低于男性。
  • 女性报告生物制剂相关不良事件率比为 1.79,显著高于男性。
  • 女性真菌感染和单纯疱疹感染率比分别为 2.20 和 3.25。

核心结论

  • 女性银屑病患者对生物制剂治疗的副作用满意度和整体满意度略低于男性。
  • 女性报告更多生物制剂相关不良事件,可能部分解释女性更常停药的现象。

研究设计与样本

  • 前瞻性、多中心、日常实践 BioCAPTURE 注册研究。
  • 纳入 315 例银屑病患者共 396 个治疗疗程(阿达木单抗 137、依那西普 90、乌司奴单抗 137、司库奇尤单抗 24、英夫利西单抗 8)。
  • 使用 TSQM 问卷纵向收集数据,采用线性混合模型分析并校正相关患者特征。

主要发现

  • 女性基线 PASI 评分显著低于男性(P=0.01)。
  • 治疗 1 年内女性 TSQM 副作用维度评分低于男性(P=0.05)。
  • 治疗 1 年内女性 TSQM 整体满意度维度评分低于男性(P=0.01)。
  • 女性报告更多相关不良事件(率比 1.79;P<0.001)。
  • 女性真菌感染(率比 2.20;P=0.001)和单纯疱疹感染(率比 3.25;P=0.005)更多。

临床怎么用

  • 临床中应关注女性银屑病患者生物制剂治疗的主观满意度和副作用主诉。
  • 对女性患者可加强感染相关不良事件的监测与预防。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Female sex has been reported as a predictor for treatment discontinuation with biological therapies for psoriasis, although reasons remain unclear. It can be hypothesized that lower satisfaction with biological treatment in women might add to the lower drug survival rates. OBJECTIVES: To identify possible differences in satisfaction with biological treatment between female and male patients using the Treatment Satisfaction Questionnaire for Medication (TSQM). METHODS: Data of psoriasis patients treated with biologics were obtained from the prospective, multicentre, daily-practice BioCAPTURE registry. Longitudinal TSQM data were analysed by linear mixed models. Relevant patient characteristics were incorporated as possible confounding factors. Post hoc analysis of adverse events was performed in order to investigate differences between sexes. RESULTS: We included 315 patients with 396 corresponding treatment episodes (137 adalimumab, 90 etanercept, 137 ustekinumab, 24 secukinumab and 8 infliximab). Almost forty per cent of the patients were female. Women had significantly lower baseline PASI scores (P = 0.01). Longitudinal analyses demonstrated lower TSQM scores for 'side-effects' (P = 0.05) and 'global satisfaction' (P = 0.01) in female patients compared with male patients over 1 year of treatment. Women reported more relevant adverse events in the context of biologic treatment compared to men (rate ratio 1.79; P < 0.001), with more fungal (rate ratio 2.20; P = 0.001) and herpes simplex infections (rate ratio 3.25; P = 0.005). CONCLUSIONS: This study provides a prospective, longitudinal analysis of treatment satisfaction with biologics in female and male patients with psoriasis. Women were slightly less satisfied with treatment regarding side-effects and global satisfaction. Differences in treatment satisfaction and side-effects might add to the fact that women discontinue biological treatments more often.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. van der Schoot LS, van den Reek JMPA, Groenewoud JMM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019. PMID: 31177583. doi:10.1111/jdv.15733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。